Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Cancer immunology, immunotherapy : CII
View this publicationCancer immunology, immunotherapy : CII
View this publicationJACC. Cardiovascular interventions
View this publicationInternational journal of bipolar disorders
View this publicationBritish journal of pharmacology
View this publicationPublication categories: Top publication
Nature neuroscience
View this publicationClinical epigenetics
View this publicationTrends in endocrinology and metabolism: TEM
View this publicationParasites & vectors
View this publicationLeukemia
View this publicationBiochemical and biophysical research communications
View this publication